New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

LiveLung, a nonprofit organization dedicated to supporting lung cancer patients, survivors and their care partners, will present a program Wednesday on the importance of lung cancer screening and ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The 10-week course at Stanford last fall was fully enrolled and packed with students eager to learn from Dr. Lin's unique ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

A study found a "significant" link between the frequency of chest X-ray referrals and improved survival rates for lung cancer ...

A groundbreaking study has revealed a significant link between the frequency of chest X-ray referrals from GPs and earlier ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...